@article{d428851039cf48f5ae301c64cb309171,
title = "Baricitinib or Tocilizumab? Treatment of Patients Hospitalized with Severe COVID-19∗",
keywords = "COVID-19, baricitinib, critical illness, immunomodulators, tocilizumab",
author = "Cawcutt, {Kelly A.} and Kalil, {Andre C.}",
note = "Funding Information: Dr. Cawcutt received funding from Becton, Dickinson and Company. Dr. Kalil has disclosed that he was an investigator for the National Institutes of Health Adaptive COVID-19 Treatment Trial. ",
year = "2023",
month = mar,
day = "1",
doi = "10.1097/CCM.0000000000005757",
language = "English (US)",
volume = "51",
pages = "413--415",
journal = "Critical care medicine",
issn = "0090-3493",
publisher = "Lippincott Williams and Wilkins",
number = "3",
}